Recommendations for the management of hepatitis C virus infection among people who inject drugs.
about
The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for preventionBarriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a reviewA systematic review of community based hepatitis C treatmentTreatment optimization for HIV/HCV co-infected patients.Inactivation of HCV and HIV by microwave: a novel approach for prevention of virus transmission among people who inject drugsEligibility of persons who inject drugs for treatment of hepatitis C virus infection.Identifying and characterizing hepatitis C virus hotspots in Massachusetts: a spatial epidemiological approach.Access to healthcare insurance and healthcare services among syringe exchange program clients in Massachusetts: qualitative findings from health navigators with the iDU ("I do") Care Collaborative.Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.Distinct features in natural history and outcomes of acute hepatitis C."Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis.Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries.Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey.Hepatitis C in European prisons: a call for an evidence-informed responseCare at the Crossroads: Navigating the HIV, HCV, and Substance Abuse Syndemic.The Cascade of Care for an Australian Community-Based Hepatitis C Treatment ServiceInjecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care.Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection.Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program.Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review.Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges.Direct-acting antiviral agents for HCV infection affecting people who inject drugs.Determinants of quality of care and treatment initiation in Medicare disabled patients with chronic hepatitis C.Limited provision of diagnostic services to Victorians living with hepatitis C antibodies, 2001-2012: a multi-level modelling analysis.The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit.Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy : Final results of the Austrian PegHope study.Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia.Retention in buprenorphine treatment is associated with improved HCV care outcomes.Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach.Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference.New hepatitis C therapies for special patient populations.Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study.Recommendations for the management of hepatitis C virus infection among people who inject drugs.Clinical outcomes in a cohort of anti-hepatitis C virus-positive patients with significant barriers to treatment referred to a Norwegian outpatient clinic.
P2860
Q26801456-931E44B1-1153-4B7C-BBA4-07EB13BA5EB2Q27010548-151145DA-7CFB-4AF8-9861-51468EC9CFB8Q27312314-624BB650-5425-48C1-9343-79B87B0C74ABQ30235034-151D35CE-65DF-4209-B580-549E41E0C176Q30369227-7D75C39F-5456-4DCA-B2FE-511EB12DD0E4Q30429470-BBB53678-AA4B-46D0-B82C-C2E0AA8C37D3Q33587555-FC415DBC-936C-43EA-9FE4-EBC6ACD4640DQ33706376-65F4EDBE-2A4B-4D8E-A1AA-49C6323F3058Q33853664-C39C416D-A8AA-4C4E-8DB7-63C3A0151394Q33955210-B83C1974-5B42-4EDC-8482-CDDDC35206DEQ34241691-CC4E2283-D1B5-4B44-8E94-F5623654DF38Q34260584-DD2881A6-FD8E-4FE2-BB75-7A097203A7BEQ34260638-13B221B0-9492-44A9-939D-C5C8B017A78CQ34260664-A29A7A80-0F4B-4381-8CDD-CB13A4C2839FQ34702334-5113F11C-8073-4F6C-8784-4F0124148E19Q35839915-F8DA28E1-3154-4C89-9497-E46E99952301Q36079786-5EDA9B30-31EA-47CC-AD92-C179AD3C408FQ36079814-D468DCDD-D13C-469E-B866-D9E871D4CC73Q36079851-4F4AF096-5A56-499D-B8EA-CF547673D43CQ36382060-EC4D115D-B180-4643-B623-BE52D9D1A439Q36654120-1CCFAE2B-F9A4-415E-BDC9-DADBFA3548B4Q36802839-37281259-C74B-4104-8AE2-09F4EF402BA0Q37245420-5E5E1FB6-0DE7-4A42-B2B7-2AE2CD110F3FQ37358615-E3658154-EB7D-4C4C-917A-C2626A412D37Q37455611-D29345FA-AC65-4161-A28F-08179B4F166EQ38573508-08915802-25AA-4941-AB7A-47AEE7B93F92Q38613271-594F0520-1027-4ECB-8F0B-3DAB95AE5DF0Q38947375-E53D9035-990B-4469-B462-2D5BDC483A51Q39138754-A6AC98C7-2849-4906-B454-1651AD7D9134Q39449112-106043C9-6435-443D-B363-8E262B43DAA0Q40044312-EB977E2D-1950-4625-86DA-221611C8A440Q40144817-189E6A37-8A56-4AE2-A99C-BB553206716EQ40317993-6E2CD3A1-1A36-4AF8-B733-982BE4D23654Q40565832-2708AE3D-F97B-4432-9250-603338353675Q40744363-8F3D9264-698F-4023-A170-11D52B82BDEFQ40818421-0EC8C295-28A3-45A9-98B0-E837FA2110E3Q40899794-14E3B542-C19D-4CF2-B84B-661A4752895BQ40959924-BC00DBAA-4600-4676-8551-116799161F71Q41047662-8E1F01CF-AF7D-4DD7-A794-F8B54BCD828CQ42240532-EA76688E-654B-4467-9941-6BD8EA3F7683
P2860
Recommendations for the management of hepatitis C virus infection among people who inject drugs.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Recommendations for the manage ...... among people who inject drugs.
@en
Recommendations for the manage ...... among people who inject drugs.
@nl
type
label
Recommendations for the manage ...... among people who inject drugs.
@en
Recommendations for the manage ...... among people who inject drugs.
@nl
prefLabel
Recommendations for the manage ...... among people who inject drugs.
@en
Recommendations for the manage ...... among people who inject drugs.
@nl
P2093
P2860
P356
P1476
Recommendations for the manage ...... among people who inject drugs
@en
P2093
Achim Kautz
Amber Arain
Andrea De Gottardi
Geert Robaeys
Gregory J Dore
Heiner Wedemeyer
Heino Stöver
International Network on Hepatitis in Substance Users
Jason Grebely
Joseph Moussalli
P2860
P304
P356
10.1093/CID/CIT302
P407
P478
57 Suppl 2
P577
2013-08-01T00:00:00Z